| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(3 months from now) | |
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(3 months from now) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(3 months from now) | |
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(1 year, 9 days from now) | |
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(8 years from now) | |
Lazanda is owned by Btcp Pharma.
Lazanda contains Fentanyl Citrate.
Lazanda has a total of 5 drug patents out of which 0 drug patents have expired.
Lazanda was authorised for market use on 30 June, 2011.
Lazanda is available in spray, metered;nasal dosage forms.
Lazanda can be used as management of breakthrough pain in patients with cancer.
The generics of Lazanda are possible to be released after 26 January, 2032.
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED;NASAL
LAZANDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic